SOIN MEDICAL CENTER (RRC360360-00)
Rural referral center, Ohio, calendar year 2025. Everything below is as the workbook stored it, with figures shown to the cent. Each section follows the Ohio Department of Health's template, in its order and words.
The name is HRSA's, from its public list of covered entities read on 11 November 2026. The workbook prints the 340B ID and no name.
About this workbook
- 340B ID
- RRC360360-00 SOIN MEDICAL CENTER (Rural referral center)
- Reporting period as typed
- January 1, 2025 - December 31, 2025
- Form
- Ohio Department of Health, ORC 3701.88 340B Covered Entity Reporting Template, calendar year 2025
Drugs dispensed in house
Drugs the covered entity dispensed through its own pharmacies.
| Row of the template | Commercial Insurance/Private Insurance | Medicare | Medicaid (all states) | Other Third-Party Payor | Uninsured/Self-Pay | Total |
|---|---|---|---|---|---|---|
| Acquisition costAggregate Acquisition Cost for all 340B drugs dispensed by the Covered Entity | $9,722 | $6,223 | $9,489 | $11,700 | $0 | $37,134 |
| Payments receivedAggregate Payments Received for all 340B drugs dispensed by the Covered Entity | $72,027 | $80,318 | $77,382 | $115,288 | $0 | $345,015 |
| All prescriptionsTotal number of Prescriptions dispensed by the Covered Entity (340B and non-340B) | 19,960 | 5,039 | 5,106 | 4,413 | 4,610 | 39,128 |
| 340B prescriptionsTotal number of Prescriptions dispensed by the Covered Entity (340B) | 3,131 | 2,573 | 2,094 | 1,701 | 0 | 9,499 |
| Percentage that were 340BPercentage of total prescriptions that were 340B | 15.69% | 51.06% | 41.01% | 38.55% | 0% | 24.28% |
Drugs dispensed through contract pharmacies
Drugs contract pharmacies dispensed on behalf of the covered entity.
| Row of the template | Commercial Insurance/Private Insurance | Medicare | Medicaid (all states) | Other Third-Party Payor | Uninsured/Self-Pay | Indeterminate (Explain) | Total |
|---|---|---|---|---|---|---|---|
| Acquisition costAggregate Acquisition Cost for all 340B drugs dispensed by all Contract Pharmacies on behalf of the Covered Entity above: | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Payments receivedAggregate Payments Received for all 340B drugs dispensed by all Contract Pharmacies on behalf of the Covered Entity above: | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All prescriptionsTotal number of Prescriptions filled by all Contract Pharmacies on behalf of the Covered Entity (340B and non-340B): | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 340B prescriptionsTotal number of 340B Prescriptions filled by all Contract Pharmacies on behalf of the Covered Entity: | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Percentage that were 340BPercentage of total Covered-Entity associated prescriptions that were 340B: | #DIV/0! | #DIV/0! | #DIV/0! | #DIV/0! | #DIV/0! | #DIV/0! | #DIV/0! |
Drugs administered
Drugs the covered entity administered, for example by infusion or injection.
| Row of the template | Commercial Insurance/Private Insurance | Medicare | Medicaid (all states) | Other Third-Party Payor | Uninsured/Self-Pay | Total |
|---|---|---|---|---|---|---|
| Acquisition costAggregate Acquisition Cost for all 340B drugs administered by the Covered Entity | $262,702 | $375,310 | $218,293 | $24,701 | $36,490 | $917,496 |
| Actual paymentsAggregate Payments Received for all 340B drugs administered by the Covered Entity - Actual Payments | $280,819 | $412,430 | $112,485 | $12,717 | $0 | $818,451 |
| Estimated paymentsAggregate Payments Received for all 340B drugs administered by the Covered Entity - Estimated Payments* | $0 | $0 | $0 | $0 | $0 | $0 |
| Total paymentsAggregate Payments Received for all 340B drugs administered by the Covered Entity - TOTAL | $280,819 | $412,430 | $112,485 | $12,717 | $0 | $818,451 |
| All prescriptionsTotal number of Prescriptions administered by the Covered Entity (340B and non-340B) | 212,526 | 590,793 | 246,829 | 25,943 | 30,738 | 1,106,829 |
| 340B prescriptionsTotal number of Prescriptions administered by the Covered Entity (340B) | 98,737 | 141,061 | 82,046 | 9,284 | 13,715 | 344,843 |
| Percentage that were 340BPercentage of total prescriptions that were 340B | 46.46% | 23.88% | 33.24% | 35.79% | 44.62% | 31.16% |
Figures are shown to the cent. The downloads keep each figure exactly as it is written in the file, and the cell file lists the workbook cell each one was read from.
Costs of running the program
Amounts in US dollars, as the workbook stores them.
| Cost | Amount | Cell |
|---|---|---|
| Contract pharmacies | $0 | C46 |
| Third-party administrators | $37,800 | C47 |
| Consultants | $22,497 | C48 |
| Software and IT | - | C49 |
| Other outside costs | - | C50 |
| Staffing | $50,850 | C53 |
| Internal IT | - | C54 |
| Other internal costs | - | C55 |
Contract pharmacies
- Number of contract pharmacies as typed
- 0
Uses of 340B funds
What the filer typed under the template's questions about how it uses the money 340B brings in. A dash or an empty cell is left out.
Narrative given where the entity cannot detail its uses, as typed
The filer in the workbook
- 340B ID as typed
- RRC360360-00
- NPIs as typed
- 1497029854
- 1760764849
Cells outside the template
The filer typed text in cells the template does not ask for. They are listed as found, by cell.
| Cell | Text |
|---|---|
| C83 | Kettering Health participates in the federal 340B Drug Pricing Program as part of its commitment to improving the health and well-being of the communities it serves. The program allows eligible Kettering Health entities to purchase outpatient medications at reduced prices, generating savings that are reinvested to expand access to care, improve affordability, and strengthen patient services. |
| C84 | Consistent with federal guidance, 340B savings are not maintained as a separate fund but are integrated into the overall financial framework of Kettering Health. These resources are strategically deployed to directly support patient care initiatives, particularly for underserved, uninsured, and underinsured populations. |
| C87 | Demonstrated Patient and Community Impact in 2025 |
| C88 | In 2025, Kettering Health’s patient assistance program supported in part by 340B savings—generated over $91.8 million in total patient support, reflecting a substantial investment in medication access and affordability. |
| C89 | Complementing these efforts, Kettering Health also provided significant levels of uncompensated care across the system, underscoring its role as a safety net provider: |
| C90 | Charity Care: $255.6 million |
| C91 | Bad Debt: $128.6 million |
| C92 | Total Uncompensated Care: $376.5 million |
| C93 | These figures highlight the magnitude of financial support provided to patients and communities and reinforce the critical role 340B savings play in sustaining these efforts. |
| C94 | Key patient assistance highlights include: |
| C95 | Infusion Support: More than $29.3 million in assistance |
| C96 | Specialty Pharmacy Programs: Over $48.5 million in total support |
| C97 | Ambulatory Care Assistance: Approximately $12.8 million |
| C98 | Together, these investments demonstrate how 340B-enabled resources are directly translated into meaningful financial relief and improved access to care. |
| C101 | Expanding Access to Care |
| C102 | Kettering Health uses 340B program savings to broaden access to essential healthcare services. These resources help offset the significant financial burden reflected in the $376.5 million in uncompensated care provided in 2025, enabling: |
| C103 | Continued care regardless of a patient’s ability to pay |
| C104 | Expansion of services in rural and underserved communities |
| C105 | Sustainability of critical programs that operate at a financial loss |
| C108 | Enhancing Medication Access and Affordability |
| C109 | Medication affordability remains a central focus of Kettering Health’s 340B strategy. The 2025 data reflect a comprehensive approach that includes: |
| C110 | Direct financial assistance to reduce patient out-of-pocket costs |
| C111 | Free drug replacement programs ensuring continuity of therapy |
| C112 | Copay support for high-cost infusion and specialty medications |
| C113 | Innovative tools such as the 340B Care Card program |
| C114 | These efforts reduce financial barriers and complement the system’s broader charity care and uncompensated care commitments. |
| C117 | Supporting and Expanding Clinical Services |
| C118 | The breadth of assistance across infusion, specialty, and ambulatory care settings reflects Kettering Health’s investment in comprehensive clinical services. 340B savings help support: |
| C119 | Advanced therapies for complex and chronic conditions |
| C120 | Specialty pharmacy management of high-cost medications |
| C121 | Integrated outpatient care models |
| C122 | These services are essential in managing the needs of patients who may otherwise contribute to uncompensated care if access were limited. |
| C125 | Addressing Social Determinants of Health |
| C126 | Kettering Health recognizes that financial hardship is a major barrier to care. The combination of $91.8 million in patient assistance and $376.5 million in uncompensated care demonstrates a system-wide commitment to reducing these barriers. |
| C127 | Additional support includes transportation, education, and care coordination services that ensure patients can access and adhere to treatment. |
| C130 | Investing in Workforce and Infrastructure |
| C131 | Delivering this level of patient and community support requires significant operational investment. 340B savings fund: |
| C132 | Clinical pharmacy teams and patient assistance coordinators |
| C133 | Infrastructure supporting specialty and infusion services |
| C134 | Technology systems for tracking and optimizing assistance |
| C135 | Compliance oversight and program integrity |
| C138 | Offsetting Financial Pressures and Sustaining Services |
| C139 | The scale of charity care and bad debt in 2025 illustrates the financial realities faced by Kettering Health. 340B savings help offset: |
| C140 | $255.6 million in charity care provided to patients in need |
| C141 | $128.6 million in bad debt associated with unpaid care |
| C142 | Reimbursement shortfalls and high-cost therapies |
| C143 | These resources are essential to sustaining access to care and maintaining critical services across the system. |
| C146 | Advancing Community and Population Health |
| C147 | Through strategic reinvestment of 340B savings, Kettering Health continues to improve community health outcomes by: |
| C148 | Reducing delays in care due to financial barriers |
| C149 | Improving medication adherence |
| C150 | Supporting chronic disease management |
| C151 | Expanding preventive care initiatives |
| C154 | Ensuring Program Integrity and Compliance |
| C155 | Kettering Health is committed to responsible stewardship of the 340B program. Program savings support: |
| C156 | Ongoing audits and monitoring |
| C157 | Staff education and compliance efforts |
| C158 | Policies and systems aligned with federal requirements |
| C161 | Summary |
| C162 | In 2025, Kettering Health demonstrated the impact of its mission-driven approach through: |
| C163 | $91.8 million in patient assistance programs |
| C164 | $376.5 million in total uncompensated care, including: |
| C165 | $255.6 million in charity care |
| C166 | $128.6 million in bad debt |
| C167 | 340B program savings are a vital component enabling Kettering Health to sustain these efforts by: |
| C168 | Expanding access to care |
| C169 | Reducing financial barriers for patients |
| C170 | Supporting high-cost and specialized therapies |
| C171 | Strengthening clinical services and infrastructure |
| C172 | Through this reinvestment, Kettering Health continues to fulfill its mission of delivering compassionate, high-quality care while addressing the evolving needs of the communities it serves. |
Differences in this workbook
No difference was found between this workbook's own figures by the rules in Methods.
Source
- Workbook
- Open RRC36036000.xlsx on the Ohio Department of Health's website
- Size
- 27 KB
- Retrieved
- 16 November 2026
- SHA-256
- 7cd25a126f07d7c7f8d18f61d165ae9130c4922ca9788497cef07744a22bb128
- How it was read
- Two separate programs read each cell of the workbook, and a value is kept when their reads agree. The cells of this workbook are listed one by one in the dataset repository.